Coronavirus Anxiety Level and COVID-19 Vaccine Attitude Among Patients With Hematological Malignancies

Basit Öğe Kaydı
dc.authoridKeklik, Muzaffer/0000-0002-6426-5249
dc.authoridCelik, Serhat/0000-0002-1052-9800
dc.contributor.authorGuven, Zeynep Tugba
dc.contributor.authorCelik, Serhat
dc.contributor.authorKeklik, Muzaffer
dc.contributor.authorUnal, Ali
dc.date.accessioned2025-01-21T16:37:12Z
dc.date.available2025-01-21T16:37:12Z
dc.date.issued2023
dc.departmentKırıkkale Üniversitesi
dc.description.abstractIntroduction: The COVID-19 vaccine is the most essential tool for altering the pandemic's trajectory. The pandemic's control is complicated by society's unwillingness to vaccinate. The aim of this cross-sectional study was to assess patients with hematological malignancies and their attitudes regarding COVID-19 immunization and to investigate COVID-19 anxiety in this susceptible population. yMethods: In this cross-sectional study, 165 patients with hematological malignancies were included. COVID-19 anxiety was evaluated with the coronavirus anxiety scale (CAS), and COVID-19 vaccine attitude was evaluated with the Vaccine Attitudes Review (VAX) scale. Results: The mean CAS score was 2.42 ( 0-17). There were 22 (13%) participants with a mean CAS score of >= 9. Half of the participants had a CAS score of 0. The CAS score was higher in females ( p = 0.023). Similarly, it was significantly higher in patients who were not in remission for hematological malignancy and who received active chemotherapy (p = 0.010). The mean VAX score was 49.07 +/- 8.76 (27-72). Most of the participants (64%) had a neutral attitude toward the COVID-19 vaccination. In a survey of 165 patients, 55% said that they were skeptical about vaccination safety, and 58% said that they were concerned about unintended side effects. In addition, 90% expressed moderate concerns about commercial profiteering. Natural immunity was preferred by 30% of the participants. There was no statistically significant correlation between CAS scores and the Vaccine Attitudes Review (VAX) scale. Conclusion: This study draws attention to the level of anxiety in patients with hematological malignancies during the COVID-19 pandemic. Negative attitudes toward the COVID-19 vaccine are worrisome for at-risk patient groups. We think that patients with hematological malignancies should be informed to eliminate their hesitations about COVID-19 vaccines.
dc.identifier.doi10.7759/cureus.38618
dc.identifier.issn2168-8184
dc.identifier.issue5
dc.identifier.pmid37284408
dc.identifier.urihttps://doi.org/10.7759/cureus.38618
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24423
dc.identifier.volume15
dc.identifier.wosWOS:001007573800026
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringernature
dc.relation.ispartofCureus Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectcoronavirus disease; covid 19; vaccination attitudes; coronavirus anxiety scale; sars-cov-2; hematological malignancy; covid-19 vaccination
dc.titleCoronavirus Anxiety Level and COVID-19 Vaccine Attitude Among Patients With Hematological Malignancies
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu